Australia - English - Department of Health (Therapeutic Goods Administration)

ipsen pty ltd - somatropin, quantity: 5 mg/ml - injection, solution - excipient ingredients: water for injections; phenol; polysorbate 20; sodium citrate dihydrate; citric acid; sodium chloride - long-term treatment of children with growth failure due to inadequate endogenous growth hormone secretion. long-term treatment of growth failure associated with turner syndrome. treatment of prepubertal children with growth failure associated with chronic renal insufficiency up to the time of renal transplantation. treatment of adults with severe growth hormone deficiency as diagnosed in the insulin tolerance test for growth hormone deficiency and defined by peak gh concentrations of less than 2.5 ng/ml.

Australia - English - Department of Health (Therapeutic Goods Administration)

ipsen pty ltd - lanreotide acetate -

Australia - English - Department of Health (Therapeutic Goods Administration)

ipsen pty ltd - clostridium botulinum type a toxin haemagglutinin complex, quantity: 500 u - injection, powder for - excipient ingredients: albumin; lactose monohydrate - dysport is indicated for symptomatic treatment of focal spasticity of: ? upper limbs in adults ? lower limbs in adults ? upper limbs in children aged 2 years and older ? lower limbs in children aged 2 years and older,dysport is indicated in adults for the treatment of: ? spasmodic torticollis ? blepharospasm ? hemifacial spasm ? moderate to severe glabellar lines and / or lateral canthal lines (crow?s feet)

Australia - English - Department of Health (Therapeutic Goods Administration)

ipsen pty ltd - clostridium botulinum type a toxin haemagglutinin complex, quantity: 125 u - injection, powder for - excipient ingredients: albumin; lactose monohydrate - dysport is indicated for symptomatic treatment of focal spasticity of: ? upper limbs in adults ? lower limbs in adults ? upper limbs in children aged 2 years and older ? lower limbs in children aged 2 years and older,dysport is indicated in adults for the treatment of: ? spasmodic torticollis ? blepharospasm ? hemifacial spasm ? moderate to severe glabellar lines and / or lateral canthal lines (crow?s feet)

Australia - English - Department of Health (Therapeutic Goods Administration)

ipsen pty ltd - clostridium botulinum type a toxin haemagglutinin complex, quantity: 300 u - injection, powder for - excipient ingredients: albumin; lactose monohydrate - dysport is indicated for symptomatic treatment of focal spasticity of: ? upper limbs in adults ? lower limbs in adults ? upper limbs in children aged 2 years and older ? lower limbs in children aged 2 years and older,dysport is indicated in adults for the treatment of: ? spasmodic torticollis ? blepharospasm ? hemifacial spasm ? moderate to severe glabellar lines and / or lateral canthal lines (crow?s feet)

Australia - English - Department of Health (Therapeutic Goods Administration)

ipsen pty ltd - clostridium botulinum type a toxin - haemagglutinin complex -

Australia - English - Department of Health (Therapeutic Goods Administration)

ipsen pty ltd - lanreotide acetate -

Australia - English - Department of Health (Therapeutic Goods Administration)

ipsen pty ltd - lanreotide acetate -

Australia - English - Department of Health (Therapeutic Goods Administration)

ipsen pty ltd - lanreotide acetate, quantity: 149.4 mg (equivalent: lanreotide, qty 125.5 mg) - injection, solution - excipient ingredients: glacial acetic acid; water for injections - somatuline autogel is indicated for: - the treatment of acromegaly when the circulating levels of growth hormone and igf-1 remain abnormal after surgery and/or radiotherapy or in patients who are dopamine agonist treatment refractory -the treatment of symptoms of carcinoid syndrome associated with carcinoid tumours -the treatment of gastroenteropancreatic neuroendocrine tumours (gep-nets) in adult patients with unresectable locally advanced or metastatic disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

ipsen pty ltd - lanreotide acetate, quantity: 113.6 mg (equivalent: lanreotide, qty 95.4 mg) - injection, solution - excipient ingredients: glacial acetic acid; water for injections - somatuline autogel is indicated for: - the treatment of acromegaly when the circulating levels of growth hormone and igf-1 remain abnormal after surgery and/or radiotherapy or in patients who are dopamine agonist treatment refractory -the treatment of symptoms of carcinoid syndrome associated with carcinoid tumours -the treatment of gastroenteropancreatic neuroendocrine tumours (gep-nets) in adult patients with unresectable locally advanced or metastatic disease.